80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]吳進(jìn)鋒 何毅輝 林 樂 魏永寶 李 濤 葉烈夫.B7-H3和PD-L1在腎細(xì)胞癌組織中的表達(dá)及臨床意義[J].福建醫(yī)藥雜志,2020,42(02):16-19.
　WU Jinfeng,HE Yihui,LIN Le,et al.Expression and clinical significance of B7-H3 and PD-L1 in renal cell carcinoma[J].FUJIAN MEDICAL JOURNAL,2020,42(02):16-19.
點(diǎn)擊復(fù)制

B7-H3和PD-L1在腎細(xì)胞癌組織中的表達(dá)及臨床意義()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期數(shù):
2020年02期
頁(yè)碼:
16-19
欄目:
臨床研究
出版日期:
2020-04-15

文章信息/Info

Title:
Expression and clinical significance of B7-H3 and PD-L1 in renal cell carcinoma
文章編號(hào):
1002-2600(2020)02-0016-05
作者:
吳進(jìn)鋒 何毅輝 林 樂 魏永寶 李 濤 葉烈夫
福建醫(yī)科大學(xué)省立臨床醫(yī)學(xué)院 福建省立醫(yī)院泌尿外科(福州 350001)
Author(s):
WU Jinfeng;  HE Yihui;  LIN Le;  WEI Yongbao;  LI Tao;  YE Liefu.
Department of Urology, Fujian Provincial Hospital,Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, China
關(guān)鍵詞:
共刺激分子B7-H3;  程序性死亡因子配體1;  共刺激分子B7-H1;  腎癌
Keywords:
B7-H3;  B7-H1;  PD-L1;  renal cell carcinoma
分類號(hào):
R737.11
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的 評(píng)估B7-H3和PD-L1在透明細(xì)胞性腎細(xì)胞癌(clear cell renal cell carcinoma,ccRCC)中的表達(dá),并探討其臨床意義。方法 采用免疫組化方法檢測(cè)88例ccRCC患者腫瘤標(biāo)本中PD-L1和B7-H3表達(dá)位置及水平,并分析二者表達(dá)與患者年齡、性別、腫瘤TNM分期、Furhman分級(jí)、是否合并靜脈癌栓及遠(yuǎn)處轉(zhuǎn)移等臨床病理參數(shù)之間的關(guān)系。結(jié)果 PD-L1在15例(17.0%)ccRCC中陽(yáng)性表達(dá),并與腫瘤TNM分期較晚、高Furhman分級(jí)、合并靜脈癌栓以及合并遠(yuǎn)處轉(zhuǎn)移等不良臨床和病理特征顯著關(guān)聯(lián)。B7-H3在21例(23.9%)腫瘤細(xì)胞和82例(93.2%)腫瘤血管內(nèi)皮細(xì)胞中陽(yáng)性表達(dá),腫瘤血管中有26.1%、25%和42.0%分別呈局灶性、中度和彌漫性表達(dá)。B7-H3在腫瘤細(xì)胞和血管內(nèi)皮細(xì)胞中的表達(dá)都與腫瘤的不良侵襲性特征存在顯著關(guān)聯(lián)。結(jié)論 B7-H3在腎癌細(xì)胞組織中表達(dá)比PD-L1更高,且在腫瘤血管內(nèi)皮細(xì)胞中廣泛表達(dá),并與腎癌的進(jìn)展密切關(guān)聯(lián)。B7-H3可能是ccRCC潛在的治療預(yù)測(cè)因子和多通路治療靶點(diǎn)。
Abstract:
Objective To evaluate the expression of B7-H3 and PD-L1 in clear cellular renal cell carcinoma and to explore its clinical significance.Methods Detect expression position and level of PD-L1 and B7-H3 in 88 specimens of ccRCC using immunohistochemical method, and analyze the relationship between the expressions and the clinical pathological parameters, such as age, gender, tumor TNM staging, Furhman grading, venous tumor emboli and distant metastasis.Results PD-L1 was positively expressed in 15 cases(17.0%)of ccRCC, and was significantly correlated with the late TNM staging, high Furhman grading, venous tumor emboli and distant metastasis.B7-H3 was positively expressed in 21 cases(23.9%)of tumor cells and 82 cases(93.2%)of tumor vascular endothelial cells, while 26.1%, 25% and 42.0% of tumor blood vessels showed localized, moderate and diffuse expression, respectively.The expression of B7-H3 in both tumor cells and vascular endothelial cells was significantly correlated with the poor invasive characteristics of the tumor.Conclusion B7-H3 is more highly expressed than PD-L1 in ccRCC, and is widely expressed in tumor blood vessels, and is closely related to the progression of ccRCC.B7-H3 may be a potential therapeutic predictor and multipathway therapeutic target.

參考文獻(xiàn)/References:

[1] Okazaki T, Chikuma S, Iwai Y, et al.A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application [J].Nat Immunol,2013, 14(12): 1212-1218.
[2] Robert C, Schachter J, Long G V, et al.Pembrolizumab versus ipilimumab in advanced melanoma [J].N Engl J Med, 2015, 372(26): 2521-2532.
[3] Reck M, Rodríguez-Abreu D, Robinson A G, et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [J].N Engl J Med, 2016, 375(19): 1823-1833.
[4] Escudier B, Motzer R J, Tannir N M, et al.Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in checkmate 214 [J/OL].Eur Urol,(2019-11-13)[2020-02-20].http://www.ncbi.nlm.nih.gov/pmc/. DOI:10.1016/j.eururo.2019.10.025
[5] Wang L, Kang F B, Shan B E, et al.B7-H3-mediated tumor immunology: Friend or foe?[J].Int J Cancer, 2014,134(12): 2764-2771.
[6] Inamura K, Yokouchi Y, Kobayashi M, et al.Tumor B7-H3(CD276)expression and smoking history in relation to lung adenocarcinoma prognosis [J].Lung Cancer, 2017, 103:44-51.
[7] Yonesaka K, Haratani K, Takamura S, et al.B7-H3 nega-tively modulates CTL-mediated cancer immunity [J].Clin Cancer Res, 2018, 24(11): 2653-2664.
[8] Crispen P L, Sheinin Y, Roth T J, et al.Tumor cell and tumor vasculature expression of b7-h3 predict survival in clear cell renal cell carcinoma [J].Clin Cancer Res, 2008, 14(16): 5150-5157.
[9] Thompson R H, Kuntz S M, Leibovich B C, et al.Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up [J].Cancer Res, 2006, 66(7): 3381-3385.
[10] Thompson R H, Gillett M D, Cheville J C, et al.Costimula-tory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma [J].Cancer, 2005, 104(10):2084-2091.
[11] Ribas A.Tumor immunotherapy directed at PD-1 [J].N Engl J Med, 2012, 366(26): 2517-2519.
[12] Choueiri T K, Figueroa D J, Fay A P,et al.Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from comparz, a randomized controlled trial [J].Clin Cancer Res, 2015, 21(5):1071-1077.
[13] Mischinger J, Fr?hlich E, Mannweiler S, et al.Prognostic value of B7-H1, B7-H3 and the SSIGN score in metastatic clear cell renal cell carcinoma [J].Cent European J Urol, 2019, 72(1): 23-31.
[14] Castellanos J R, Purvis I J, Labak C M, et al.B7-H3 role in the immune landscape of cancer [J].Am J Clin Exp Immunol, 2017, 6(4): 66-75.
[15] Patel S P, Kurzrock R.PD-L1 Expression as a predictive biomarker in cancer immunotherapy [J].Mol Cancer Ther, 2015, 14(4): 847-856.
[16] Brahmer J, Reckamp K L, Baas P, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [J].N Engl J Med,2015, 373(2):123-135.

備注/Memo

備注/Memo:
基金項(xiàng)目:福建省自然科學(xué)基金資助項(xiàng)目(2016J01493)
更新日期/Last Update: 2020-04-15